EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
about
Robust estimates of overall immune-repertoire diversity from high-throughput measurements on samplesTumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy.Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and DosimetryExpansion of Bone Marrow Adipose Tissue During Caloric Restriction Is Associated With Increased Circulating Glucocorticoids and Not With Hypoleptinemia.Effective radiation dose of a MSCT, two CBCT and one conventional radiography device in the ankle region.Why does starvation make bones fat?Proliferative and Glycolytic Assessment of the Whole-Body Bone Marrow Compartment.Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.Estimating (131)I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification.Investigation of effect of variations in bone fraction and red marrow cellularity on bone marrow dosimetry in radio-immunotherapy.Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy.The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.Depth-dependent concentrations of hematopoietic stem cells in the adult skeleton: Implications for active marrow dosimetry.Imaging and dosimetry for radium-223: the potential for personalized treatment.The role of patient-based treatment planning in peptide receptor radionuclide therapy.Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.An analytical method for computing voxel S values for electrons and photons.Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.Evaluation of sequential SPECT and CT for targeted radionuclide therapy dosimetry.Effective Radiation Dose in the Wrist Resulting from a Radiographic Device, Two CBCT Devices and One MSCT Device: A Comparative Study.Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance.Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.Validation of simplified dosimetry approaches in ⁸⁹Zr-PET/CT: the use of manual versus semi-automatic delineation methods to estimate organ absorbed doses.Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.Molecular Interaction of Bone Marrow Adipose Tissue with Energy Metabolism.Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer.Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature reviewPatient-specific image-based bone marrow dosimetry in Lu-177-[DOTA,Tyr]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
P2860
Q28829850-F3A8768F-EB92-45A7-9566-CC9CE4DF3F05Q33427043-B0AE5789-13AA-446F-9C03-BE75D30A9E45Q33802694-F2FBABD6-332F-4538-96B5-36D19F2E029AQ34506286-6F128946-0961-4700-96FB-523E9F7EB8B5Q35186267-BE9C3000-1EC6-413F-99A9-7ECA7C3F3768Q35202573-EC163D35-9823-4CCF-8C5F-FAF682F70B34Q36038787-A3C21A7E-A54E-4739-8D49-53BFE5624B12Q36128368-0E343247-FE6B-4001-BC67-91E0CB5ADFA8Q36563416-6DC83246-94ED-49A2-9F84-CDD09CBABBA3Q36662850-13927521-C433-4B2A-B9F5-BFA6FE5C6CFFQ37079244-D6611A03-D420-4C98-90F7-5C35F3711E24Q37606049-70311373-E091-42DC-A599-73674F0418C3Q37608115-466E8A55-0567-4CE4-AE43-3903E377347BQ38219225-FB83CEDF-FCB7-4126-8957-97F13B10D0D9Q38271733-DA127CCE-6F94-49E2-BD4F-834FD64B9FB7Q38992783-EF531AEC-8DC9-4DAA-A795-07601A353B89Q39400630-99DD177E-1713-4B83-BFC0-C04FDE0DDC40Q40311407-9BF63CB6-476C-42CA-8AD4-764818971709Q40676597-AEDA35CB-E4B3-466F-B8DA-CEBA3F0C6956Q40777229-1BAE400A-C76D-4952-8F37-7570E61225C6Q42345704-55ECB1CA-EFBC-4F29-A95A-F097F4ECDEE9Q44673300-15310645-89EA-41CC-BB63-1D8DCAD53458Q46062061-1259009C-A8B7-41B9-85D1-1BEB66751B30Q47163935-0EE8123B-AB49-4926-82A2-7003356E27A6Q47343725-171B95B2-5D4D-4987-9CD0-A05C9DA04EF5Q47436682-EEEC3148-A313-41D3-9A97-68A217A33EFEQ47680976-D2EF9B2E-A7E1-4179-9DA9-02226FA409D3Q50485352-91D3822E-D3C3-436A-8DDA-D7031E7B6057Q50545742-39AF50D1-B30C-4984-8BB5-62E357F8F3C2Q53047632-2A917BBB-33D8-428D-B100-B2AE97E59015Q53163035-580FE86C-D6B1-4BBC-B0DD-B186D5DA9298Q53363420-614ACF86-3E45-41D3-8F1A-30A221AF3EE7Q53695831-8B17BB0C-29EE-4BFB-AAD1-23394ADA45CFQ55033208-731CB78A-8991-44CD-9FDF-A087A95B427AQ55603732-718D57D5-765A-46E5-8BE1-5C8D0588E2D3Q58695846-5A92919E-5908-4574-AE58-30DCAE8B1D88Q58801951-8EBAC92E-A50C-4ED9-AD02-17E34C4AB097
P2860
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
@en
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
@nl
type
label
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
@en
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
@nl
prefLabel
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
@en
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
@nl
P2093
P1476
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.
@en
P2093
Carlo Chiesa
Cecilia Hindorf
EANM Dosimetry Committee
Gerhard Glatting
Glenn Flux
Ola Lindén
P2888
P304
P356
10.1007/S00259-010-1422-4
P577
2010-06-01T00:00:00Z